Research
What we do.
Lophora is built upon a foundation of scientific excellence. The founders of the company have emerged from more than fifteen years of academic research in the field neuroscience with a market changing invention to treat TRD. Lophora presents a clinical candidate with properties superior to Psilocybin.
Paving the way
Almost two decades of research into the serotonin 2A receptor by Lophora co-founders Prof. Jesper Kristensen and Prof. Anders Jensen has lead to the discovery of some of the most selective and potent known agonists at this receptor target.[1][2][3]
Some of these compounds have been used to develop radioimaging tools for visualizing the effect of 2A agonists in the human brain through the CIMBI project.[4]
Further investigation on the structure activity relationship for this receptor has lead to the discovery of LPH-5 and the founding of Lophora.
LPH-5
We have identified a novel proprietary chemotype of potent and highly selective 5-HT2AR agonists, mirroring the effects of Psilocybin. The compounds exhibit excellent drug-like properties, and a preclinical candidate, LPH-5, has been identified.
Current status
Through PoC funding granted by the BioInovation institute (BII). Lophora has successfully finished initial characterization of our lead-candidate and now seek funding toward IND status and first in human trials. The company is currently enrolled in the BII Business Accelerator Program. Lophora has a unique position in the market for anti-depressant therapies of the future. The company seeks to mature our lead-candidate through pre-clinical operations toward “first in human”-trials by acquiring IND status by 2021. Given our unique technology and knowledge of the field, we are confident that we are moving ahead of a global market shift towards medically aided psychotherapy as a treatment for TRD.
Funding
Through PoC funding granted by the BioInovation institute (BII). Lophora has successfully finished initial characterization of our lead-candidate and now seek funding toward IND status and first in human trials. The company is currently enrolled in the BII Business Accelerator Program.
Want to know more?
Get in contact with the Lophora team. We would be happy to hear from you.